121 related articles for article (PubMed ID: 10340602)
1. Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506.
Ohkubo M; Kojiri K; Kondo H; Tanaka S; Kawamoto H; Nishimura T; Nishimura I; Yoshinari T; Arakawa H; Suda H; Morishima H; Nishimura S
Bioorg Med Chem Lett; 1999 May; 9(9):1219-24. PubMed ID: 10340602
[TBL] [Abstract][Full Text] [Related]
2. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
[TBL] [Abstract][Full Text] [Related]
3. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
[TBL] [Abstract][Full Text] [Related]
4. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor activities in mice.
Arakawa H; Iguchi T; Morita M; Yoshinari T; Kojiri K; Suda H; Okura A; Nishimura S
Cancer Res; 1995 Mar; 55(6):1316-20. PubMed ID: 7882329
[TBL] [Abstract][Full Text] [Related]
5. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
6. In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites.
Takenaga N; Ishii M; Nakajima S; Hasegawa T; Iwasa R; Ishizaki H; Kamei T
Drug Metab Dispos; 1999 Feb; 27(2):205-12. PubMed ID: 9929504
[TBL] [Abstract][Full Text] [Related]
7. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
[TBL] [Abstract][Full Text] [Related]
8. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
Yoshinari T; Ohkubo M; Fukasawa K; Egashira S; Hara Y; Matsumoto M; Nakai K; Arakawa H; Morishima H; Nishimura S
Cancer Res; 1999 Sep; 59(17):4271-5. PubMed ID: 10485471
[TBL] [Abstract][Full Text] [Related]
9. DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.
Facompre M; Carrasco C; Colson P; Houssier C; Chisholm JD; Van Vranken DL; Bailly C
Mol Pharmacol; 2002 Nov; 62(5):1215-27. PubMed ID: 12391286
[TBL] [Abstract][Full Text] [Related]
10. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.
Takenaga N; Hasegawa T; Ishii M; Ishizaki H; Hata S; Kamei T
Drug Metab Dispos; 1999 Feb; 27(2):213-20. PubMed ID: 9929505
[TBL] [Abstract][Full Text] [Related]
11. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
12. Indolocarbazole glycosides in inactive conformations.
Facompré M; Carrasco C; Vezin H; Chisholm JD; Yoburn JC; Van Vranken DL; Bailly C
Chembiochem; 2003 May; 4(5):386-95. PubMed ID: 12740810
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.
Cavazos CM; Keir ST; Yoshinari T; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2001 Sep; 48(3):250-4. PubMed ID: 11592348
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activities of NB-506 analogues: Effects of the positions of two hydroxyl groups at the indole rings.
Ohkubo M; Nishimura T; Honma T; Nishimura I; Ito S; Yoshinari T; Suda HA; Morishima H; Nishimura S
Bioorg Med Chem Lett; 1999 Dec; 9(23):3307-12. PubMed ID: 10612590
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anticancer activity of new pyrrolocarbazoles and pyrrolo-beta-carbolines.
Laronze M; Boisbrun M; Léonce S; Pfeiffer B; Renard P; Lozach O; Meijer L; Lansiaux A; Bailly C; Sapi J; Laronze JY
Bioorg Med Chem; 2005 Mar; 13(6):2263-83. PubMed ID: 15830466
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activities of NB-506 analogues modified at the glucose group.
Ohkubo M; Nishimura T; Kawamoto H; Nakano M; Honma T; Yoshinari T; Arakawa H; Suda H; Morishima H; Nishimura S
Bioorg Med Chem Lett; 2000 Mar; 10(5):419-22. PubMed ID: 10743939
[TBL] [Abstract][Full Text] [Related]
17. Rebeccamycin analogues from indolo[2,3-c]carbazole.
Voldoire A; Sancelme M; Prudhomme M; Colson P; Houssier C; Bailly C; Léonce S; Lambel S
Bioorg Med Chem; 2001 Feb; 9(2):357-65. PubMed ID: 11249128
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model.
Balasubramanian BN; St Laurent DR; Saulnier MG; Long BH; Bachand C; Beaulieu F; Clarke W; Deshpande M; Eummer J; Fairchild CR; Frennesson DB; Kramer R; Lee FY; Mahler M; Martel A; Naidu BN; Rose WC; Russell J; Ruediger E; Solomon C; Stoffan KM; Wong H; Wright JJ; Zimmermann K; Vyas DM
J Med Chem; 2004 Mar; 47(7):1609-12. PubMed ID: 15027851
[TBL] [Abstract][Full Text] [Related]
19. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.
Bailly C; Dassonneville L; Colson P; Houssier C; Fukasawa K; Nishimura S; Yoshinari T
Cancer Res; 1999 Jun; 59(12):2853-60. PubMed ID: 10383146
[TBL] [Abstract][Full Text] [Related]
20. Methylenedioxy- and ethylenedioxy-fused indolocarbazoles: potent human topoisomerase I inhibitors and antitumor agents.
Zembower DE; Xie Y; Koohang A; Kuffel MJ; Ames MM; Zhou Y; Mishra R; Mar AA; Flavin MT; Xu ZQ
Anticancer Agents Med Chem; 2012 Nov; 12(9):1117-31. PubMed ID: 22339065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
